$MRZM
Marizyme Inc Stock $mrzm

$mrzm Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224021617 Filed on May 28, 2024

Income Statement

Concept	2024 Q1	2023 Q1	2023
Revenue	$32.86K	$129.0K	$645.8K
YoY Change	-74.53%		176.6%
Cost Of Revenue	$9.647K	$39.28K	$188.1K
YoY Change	-75.44%		246.3%
Gross Profit	$23.21K	$89.70K	$457.7K
YoY Change	-74.13%		155.46%
Gross Profit Margin	70.64%	69.55%	70.87%
Selling, General & Admin	$962.7K	$1.370M	$17.06M
YoY Change	-29.73%	-46.62%	104.77%
% of Gross Profit	4148.14%	1527.4%	3727.99%
Research & Development	$321.9K	$606.0K	$2.177M
YoY Change	-46.89%	-50.26%	-45.29%
% of Gross Profit	1386.88%	675.59%	475.58%
Depreciation & Amortization	$108.8K	$210.3K	$841.2K
YoY Change	-48.28%	-0.01%	-0.03%
% of Gross Profit	468.72%	234.49%	183.79%
Operating Expenses	$1.395M	$2.223M	$34.54M
YoY Change	-37.22%	-44.37%	-7.89%
Operating Profit	-$1.372M	-$2.133M	-$34.09M
YoY Change	-35.67%	-46.62%	-8.67%
Interest Expense	-$4.162M	-$1.698M	-$30.22M
YoY Change	145.15%	466.77%	983.59%
% of Operating Profit
Other Income/Expense, Net	-$4.854M	-$421.7K	-$31.26M
YoY Change	1051.1%	-76.96%	3612.31%
Pretax Income	-$6.226M	-$2.555M	-$65.35M
YoY Change	143.73%	-58.29%	71.22%
Income Tax
% Of Pretax Income
Net Earnings	-$6.226M	-$2.555M	-$65.35M
YoY Change	143.73%	-58.29%	71.22%
Net Earnings / Revenue	-18950.82%	-1980.7%	-10118.6%
Basic Earnings Per Share	-$0.05	-$0.06	-$1.44
Diluted Earnings Per Share	-$0.05	-$0.06	-$1.44
COMMON SHARES
Basic Shares Outstanding	131.8M shares	40.77M shares	45.47M shares
Diluted Shares Outstanding	131.8M shares	40.76M shares	45.47M shares

Balance Sheet

Concept	2024 Q1	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.150K	$329.8K	$148.5K
YoY Change	-98.14%	-89.61%	-70.94%
Cash & Equivalents	$6.146K	$329.8K
Short-Term Investments
Other Short-Term Assets	$677.8K	$1.259M	$699.4K
YoY Change	-46.17%	167.97%	-37.87%
Inventory	$15.21K	$176.5K	$24.86K
Prepaid Expenses	$677.8K	$1.259M
Receivables		$78.17K	$60.28K
Other Receivables	$35.82K	$35.23K	$35.80K
Total Short-Term Assets	$735.0K	$1.879M	$968.8K
YoY Change	-60.88%	-49.05%	-50.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.50K	$12.50K	$1.114M
YoY Change	0.0%	-98.87%	-25.63%
Goodwill	$5.416M	$7.191M
YoY Change	-24.68%
Intangibles		$27.46M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$150.5K	$332.9K	$152.5K
YoY Change	-54.79%	-9.8%	-58.69%
Total Long-Term Assets	$20.84M	$36.39M	$21.05M
YoY Change	-42.75%	-40.66%	-42.7%
TOTAL ASSETS
Total Short-Term Assets	$735.0K	$1.879M	$968.8K
Total Long-Term Assets	$20.84M	$36.39M	$21.05M
Total Assets	$21.57M	$38.27M	$22.02M
YoY Change	-43.64%	-41.14%	-43.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.584M	$1.873M	$2.216M
YoY Change	37.96%	127.71%	81.0%
Accrued Expenses	$436.8K	$426.1K	$539.8K
YoY Change	2.5%	53.76%	-4.37%
Deferred Revenue
YoY Change
Short-Term Debt	$5.448M	$0.00	$2.694M
YoY Change		-100.0%
Long-Term Debt Due	$17.11M	$5.639M	$14.92M
YoY Change	203.39%		1217.23%
Total Short-Term Liabilities	$25.85M	$8.027M	$20.60M
YoY Change	222.01%	384.72%	605.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$792.2K	$0.00
YoY Change	-100.0%	149.08%	-100.0%
Other Long-Term Liabilities	$6.555M	$14.22M	$6.073M
YoY Change	-53.9%	-20.05%	-61.05%
Total Long-Term Liabilities	$6.555M	$15.01M	$6.073M
YoY Change	-56.33%	-17.08%	-66.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.85M	$8.027M	$20.60M
Total Long-Term Liabilities	$6.555M	$15.01M	$6.073M
Total Liabilities	$32.40M	$23.04M	$26.68M
YoY Change	40.65%	16.59%	25.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$157.6M	-$88.54M
YoY Change	77.95%
Common Stock	$131.8K	$40.77K
YoY Change	223.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.83M	$15.23M	-$4.661M
YoY Change
Total Liabilities & Shareholders Equity	$21.57M	$38.27M	$22.02M
YoY Change	-43.64%	-41.14%	-43.1%

Cashflow Statement

Concept	2024 Q1	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$6.226M	-$2.555M	-$65.35M
YoY Change	143.73%	-58.29%	71.22%
Depreciation, Depletion And Amortization	$108.8K	$210.3K	$841.2K
YoY Change	-48.28%	-0.01%	-0.03%
Cash From Operating Activities	-$809.0K	-$1.120M	-$4.685M
YoY Change	-27.78%	-74.03%	-56.83%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$666.6K	$939.1K	$4.322M
YoY Change	-29.01%	-72.5%	-40.71%
NET CHANGE
Cash From Operating Activities	-$809.0K	-$1.120M	-$4.685M
Cash From Investing Activities
Cash From Financing Activities	$666.6K	$939.1K	$4.322M
Net Change In Cash	-$142.3K	-$181.1K	-$362.4K
YoY Change	-21.4%		-89.82%
FREE CASH FLOW
Cash From Operating Activities	-$809.0K	-$1.120M	-$4.685M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q1	MRZM	Shares Issued For Legal Settlement SharesIssuedForLegalSettlement		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q4	us-gaap	Notes Payable NotesPayable		usd
CY2023Q1	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
CY2023Q1	MRZM	Debt Accretion Expenses DebtAccretionExpenses		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold		usd
CY2024Q1	us-gaap	Cash Cash	6146	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	60284	usd
CY2024Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	35823	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	677811	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	15209	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	734989	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12500	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12500	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1000702	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14255352	usd
CY2024Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	120500	usd
CY2024Q1	us-gaap	Deposit Assets DepositAssets	30000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	5416000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	20835054	usd
CY2024Q1	us-gaap	Assets Assets	21570043	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2584044	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1300532	usd
CY2024Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	15807061	usd
CY2024Q1	MRZM	Convertible Debt Original Issue Discount Current ConvertibleDebtOriginalIssueDiscountCurrent	5448468	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	436795	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	25847800	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	563907	usd
CY2024Q1	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	5991000	usd
CY2023Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	5406000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6554907	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6073129	usd
CY2024Q1	us-gaap	Liabilities Liabilities	32402707	usd
CY2023Q4	us-gaap	Liabilities Liabilities	26675711	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	131793088	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	131793088	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	131792	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	131792	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	146598185	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	146543921	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157562641	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151336349	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10832664	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4660636	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21570043	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22015075	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32855	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	128974	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	9647	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	39275	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	23208	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	89699	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	264096	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	384806	usd
CY2024Q1	us-gaap	Salaries And Wages SalariesAndWages	310159	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	266968	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	321867	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	605997	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	54264	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	210966	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	108777	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	210338	usd
CY2024Q1	us-gaap	Royalty Expense RoyaltyExpense	1957	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	36183	usd
CY2024Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	334180	usd
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	507324	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	1395300	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2222582	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1372092	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2132883	usd
CY2024Q1	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	4161830	usd
CY2023Q1	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	1697701	usd
CY2024Q1	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-585000	usd
CY2023Q1	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1276000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-107370	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4854200	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-421701	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6226292	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554584	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-181060	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148465	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	131793088	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131793088	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40757524	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40757524	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17421985	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	210966	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	153600	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554584	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15231967	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4660636	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4660636	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	54264	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6226292	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10832664	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10832664	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6226292	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554584	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	108777	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	210338	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	100509	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94981	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	54264	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	210966	usd
CY2024Q1	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	4161830	usd
CY2023Q1	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	1697701	usd
CY2024Q1	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-585000	usd
CY2023Q1	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	1276000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-107370	usd
CY2023Q1	MRZM	Shares Issued For Legal Settlement SharesIssuedForLegalSettlement	153600	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-60258	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	10284	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-21566	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	133469	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9646	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-39039	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	167374	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	358540	usd
CY2024Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	40747	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	89016	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-808951	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1120156	usd
CY2024Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	755000	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	88368	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	60904	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	666632	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	939096	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-142319	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	510865	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6146	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	329805	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157562641	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151336349	usd
CY2024Q1	MRZM	Working Capital WorkingCapital	-25112811	usd
CY2023Q4	MRZM	Working Capital WorkingCapital	-19633804	usd
CY2024Q1	us-gaap	Cash Cash	6146	usd
CY2023Q4	us-gaap	Cash Cash	148465	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zaqV2dMcxbrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z4KrfMlTZqm6">Use of Estimates</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, and contingent liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	MRZM	Midrange Average Estimated Interest Rate MidrangeAverageEstimatedInterestRate	0.206	pure
CY2024Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	627000	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3985000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3358000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1128078	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1101211	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	436795	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	434082	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	563907	usd
CY2020Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	five-and-a-half-year lease agreement
CY2020Q4	us-gaap	Area Of Land AreaOfLand	10300	sqft
CY2022Q2	us-gaap	Area Of Land AreaOfLand	3053	sqft
CY2024Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y3M29D
CY2024Q1	us-gaap	Payments For Rent PaymentsForRent	97173	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	154828	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1000702	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	667129	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1000702	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1101211	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	325562	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	444934	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	266034	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1036530	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	35828	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1000702	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15850745	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1595393	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14255352	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29142745	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2308896	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	12469720	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14364129	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5416000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	5416000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27675020	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	12469720	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	841171	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14364129	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	108777	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14255352	usd
CY2024Q1	us-gaap	Notes Payable NotesPayable	755000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4260594	shares
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6692765	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4180071	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6500743	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	684682	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4207828	shares
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	344959	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	9340774	usd
CY2024Q1	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	2091490	usd
CY2023Q1	MRZM	Interest And Accretion Expense InterestAndAccretionExpense	2763749	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1128078	usd
CY2024Q1	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	680135	usd
CY2024Q1	MRZM	Debt Accretion Expenses DebtAccretionExpenses	2074078	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	131793088	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	131793088	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	131793088	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	131793088	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y21D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3925943	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y21D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	165000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.48
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3760943	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3570943	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.29
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M10D
CY2024Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5000000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1128078	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	54264	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	210966	usd
CY2024Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	72100	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	243750	usd

Files In Submission

Name	View Source	Status
0001493152-24-021617-index-headers.html	Edgar Link	pending
0001493152-24-021617-index.html	Edgar Link	pending
0001493152-24-021617.txt	Edgar Link	pending
0001493152-24-021617-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrzm-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
mrzm-20240331_cal.xml	Edgar Link	unprocessable
mrzm-20240331_lab.xml	Edgar Link	unprocessable
mrzm-20240331_def.xml	Edgar Link	unprocessable
mrzm-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRZM
Marizyme Inc Stock $mrzm

2024 Q1 Form 10-Q Financial Statement

#000149315224021617 Filed on May 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM Marizyme Inc Stock $mrzm

2024 Q1 Form 10-Q Financial Statement

#000149315224021617 Filed on May 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM
Marizyme Inc Stock $mrzm